Questions about Cardiomyopathy
What causes sepsis-induced cardiomyopathy and what new treatments are available for it?
Sepsis-induced cardiomyopathy is caused by inflammation, mitochondrial damage, and calcium handling problems. New treatments include repurposed drugs, traditional Chinese medicine, and targeted therapies, but most need more testing.
Full answer →Is the drug ifetroban safe for boys with Duchenne muscular disease and cardiomyopathy?
There is no confirmed safety data for ifetroban in boys with Duchenne muscular dystrophy and cardiomyopathy because the relevant Phase 2 trial has not yet published safety results.
Full answer →Does having LGE-CMR positivity mean a higher risk of sudden death for cardiomyopathy patients?
Yes, LGE-CMR positivity is linked to a higher risk of sudden cardiac death in cardiomyopathy patients, especially those with non-ischemic cardiomyopathy.
Full answer →All Cardiomyopathy Articles
- Vascular smooth muscle cell immune interactions drive remodeling across cardiovascular diseases
- Review of Diabetic Cardiomyopathy without reported trial data or specific outcomes
- Mini review examines sudden cardiac death risks in marathon runners across different age groups
- Meta-analysis reveals CMR and biomarkers key in ICI myocarditis
- Narrative review discusses Ganoderma lucidum polysaccharides for diabetes and related complications
- Deep learning model screens for transthyretin amyloid cardiomyopathy using ECG images
- Systematic review and meta-analysis of MYH7 versus MYBPC3 variants in obstructive hypertrophic cardiomyopathy
- Acoramidis associated with lower diuretic intensification in transthyretin amyloid cardiomyopathy
- PSI-QPI metrics improved prediction of TTN-TV disease penetrance and expressivity in cardiomyopathy patients
- Thyroid dysfunction and atrial fibrillation risk in hypertrophic obstructive cardiomyopathy patients
- Review of Visual Standardized Quantification for LGE in Cardiomyopathy
- Review synthesizes genetic insights and CMR imaging traits as potential therapeutic targets for cardiomyopathies
- Narrative review covers cardiovascular conditions and cognitive decline without reported trial data
- Echocardiographic and biochemical markers predict mortality in children with hypertrophic cardiomyopathy
- Review proposes pragmatic framework for pediatric heart failure management addressing myocarditis and MIS-C
- Deep learning model improves LVOT obstruction classification in hypertrophic cardiomyopathy patients
- Geranylgeranylacetone mitigates desmin variant-induced atrial cardiomyopathy mechanisms in vitro
- GWAS meta-analysis identifies 89 loci for mitral valve prolapse and genetic links to hypertrophic cardiomyopathy
- Serum biomarkers stratify disease severity in acute myocarditis cohorts
- Plasma proteins linked to HCM severity identified in MYBPC3 carriers and UK Biobank
- AI-assisted echocardiography shows moderate agreement with cardiologists in ATTR-CM monitoring
- AI-derived echocardiographic measurements predict outcomes in transthyretin cardiomyopathy patients
- DCM Consortium PIs Rate Traditional Genetic Care Models More Acceptable Than Physician-Led Models
- Systematic review identifies shared immune mechanisms and therapeutic targets across cardiovascular inflammatory diseases
- Cardiac genetic testing mainstreaming increases uptake and reduces wait times but lowers informed decision making
- Systematic review finds evidence gap for amiodarone in chronic Chagas cardiomyopathy
- LGE-CMR positivity associates with higher sudden cardiac death risk in ICD and CRT candidates
- ACIP concludes benefits of mRNA COVID-19 vaccination outweigh myocarditis risks
- Early age onset predicts MACE in pediatric cardiomyopathy patients with TTN variants
- Tofacitinib used in single case of steroid-refractory multi-organ immune-related adverse events
- Deep learning model predicts left atrial imaging from ECG, improves AF and HF risk stratification
- Phase 2 trial of oral ifetroban in DMD cardiomyopathy reports no safety results yet
- Systematic review explores pathogenesis and emerging treatments for sepsis-induced cardiomyopathy
- SGLT2 inhibitors associated with lower mortality in ATTR-CM patients receiving disease-modifying therapy
- Case report identifies likely pathogenic TNNT2 variant in Chinese DCM patient; review finds 14 variants
- Multimodality cardiac imaging aids differentiation between hypertrophic cardiomyopathy and cardiac amyloidosis
- MAPSE Predicts Adverse Events in Acute Myocarditis; Lateral MAPSE Shows Superior Performance